Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM) will showcase its innovative gene editing technologies at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 4:00 p.m. ET. CEO John Evans will participate in a fireside chat, offering insights into the company's base editing platform, which allows precise genetic modifications without double-stranded breaks in DNA. This event reflects Beam's commitment to pioneering precision genetic medicines and its ongoing development of internal manufacturing capabilities. Interested parties can access the live webcast and its 60-day archive on Beam's investor website.

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 4:00 p.m. ET.

The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com 

Media:
Dan Budwick
1AB
dan@1abmedia.com 

FAQ

When is Beam Therapeutics participating in the Jefferies Gene Therapy/Editing Summit?

Beam Therapeutics will participate in the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 4:00 p.m. ET.

Who is the speaker from Beam Therapeutics at the summit?

CEO John Evans will speak during the fireside chat at the Jefferies Gene Therapy/Editing Summit.

How can I watch the Beam Therapeutics presentation at the summit?

The presentation can be watched live on Beam's investor website, and will also be archived for 60 days after the event.

What technology does Beam Therapeutics focus on?

Beam Therapeutics specializes in base editing, a precision gene editing technology that makes single base modifications in genomic sequences.